Biotage invests in biomolecule purification
Biotage AB (BIOT.ST) today announces that the company invests 15 MDKK into the biomolecule area through the subscription of new shares in the Danish company Chreto Aps. Biomolecules is one of the fastest growing areas in drug development today and includes monoclonal antibodies-based drugs being used for the treatment of various diseases like for example rheumatoid arthritis, and cancer. The routes to developing biomolecules do not follow the same synthetic pathways as small molecule drug development, and today the purification of biomolecules is often complicated and expensive. ”This